Literature DB >> 32729264

Halo, Reversed Halo, or Both? Atypical Computed Tomography Manifestations of Coronavirus Disease (COVID-19) Pneumonia: The "Double Halo Sign".

Antonio Poerio1, Matilde Sartoni2, Giammichele Lazzari2, Michele Valli3, Miria Morsiani2, Maurizio Zompatori4.   

Abstract

The epidemic of 2019 novel coronavirus, later named as coronavirus disease (COVID-19), began in Wuhan, China in December 2019 and has spread rapidly worldwide. Early diagnosis is crucial for the management of the patients with COVID-19, but the gold standard diagnostic test for this infection, the reverse transcriptase polymerase chain reaction, has a low sensitivity and an increased turnaround time. In this scenario, chest computed tomography (CT) could play a key role for an early diagnosis of COVID-19 pneumonia. Here, we have reported a confirmed case of COVID-19 with an atypical CT presentation showing a "double halo sign," which we believe represents the pathological spectrum of this viral pneumonia.
Copyright © 2020 The Korean Society of Radiology.

Entities:  

Keywords:  Atypical CT manifestation; COVID-19 pneumonia; Case report; Chest CT; SARS-CoV-2

Mesh:

Year:  2020        PMID: 32729264      PMCID: PMC7458858          DOI: 10.3348/kjr.2020.0687

Source DB:  PubMed          Journal:  Korean J Radiol        ISSN: 1229-6929            Impact factor:   3.500


INTRODUCTION

Coronavirus disease (COVID-19) originated in Wuhan, Hubei Province of China in December 2019 and has spread rapidly worldwide, starting from Italy where more than 220000 confirmed cases and more than 32000 deaths have been registered to date (123). In February 2020, the World Health Organization named this new coronavirus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting disease as COVID-19 (45). Reverse transcriptase polymerase chain reaction (RT-PCR), which is usually performed on the oropharyngeal swab, is the gold standard test for the diagnosis of COVID-19, but it has a low sensitivity and an increased turnaround time (approximately 24–48 hours). Hence, several studies have highlighted the role and usefulness of chest computed tomography (CT) for an early diagnosis of COVID-19 pneumonia (678). We present a case of COVID-19 pneumonia with an atypical and never described CT presentation pattern. Since no personal identifiable data were reported, this study was exempted from the Institutional Review Board approval; however, we obtained written informed consent from the patient.

CASE REPORT

A 55-year-old woman with a history of cough, fever, and worsening dyspnea for 7 days, was referred to the emergency department of the Imola City Hospital. She had no relevant medical history, except for mild arterial hypertension, which was been treated with amlodipine (5 mg/day) and valsartan/hydrochlorothiazide (160/12.5 mg/day). On admission, her body temperature was slightly elevated (38.2℃) and oxygen saturation was 93%. An arterial blood gas analysis showed the arterial partial pressure of oxygen and the fraction of inspired oxygen ratio of 301. Laboratory studies showed a normal neutrophil count (68.2%; normal range: 42.0–77.0%), mild lymphopenia (18.1%; normal range: 20.0–40.0%), an increased erythrocyte sedimentation rate (76 mm/h; normal range: < 36 mm/h), and elevated C-reactive protein level (5.77 mg/dL; normal range: < 0.50 mg/dL). Based on an oropharyngeal swab, the patient tested positive for SARS-CoV-2 by the RT-PCR test. Unenhanced high-resolution chest CT revealed multiple consolidations in both the lungs, mostly with nodular morphology (approximately 1–1.5 cm), but some consolidations were larger in size (the largest approximately 5 cm) with prevalent peripheral and subpleural distribution and without a clear predominance for upper or lower lung fields. All of these consolidations were surrounded by a well-defined ground-glass opacity, the “halo sign” (910) (Fig. 1). Numerous recent publications reporting COVID-19 pneumonia have indicated that the “halo sign” is atypical and infrequent, but not an entirely rare finding in this infection (1112). In the right lower lobe (RLL), these consolidations showed a tendency toward confluence and at least three of them had peculiar CT features, with an organizing pneumonia (OP) like pattern represented by a rounded area of normal parenchyma or rounded ground-glass opacity surrounded by a complete ring of consolidation, known as “reversed halo sign” or “atoll sign,” a well-known pattern of OP (913). This was surrounded in turn by another peripheral ground-glass halo (identical to the “halo sign” of the other consolidations) that gave these lesions a peculiar target-like appearance, which we defined as “double halo sign” (Figs. 2, 3).
Fig. 1

Chest-CT on hospital admission.

Axial (A) and coronal (B) images show multiple bilateral rounded consolidations with surrounding well-defined ground-glass opacities (“halo sign”).

Fig. 2

Chest-CT multi-planar reconstructions of the “double halo sign.”

Axial (A), sagittal (B), and coronal (C) images show rounded areas of normal parenchyma or rounded ground-glass opacities surrounded by a more or less complete ring of consolidation surrounded in turn by another peripheral ground-glass halo with a final target-like appearance that we defined as “double halo sign.”

Fig. 3

Magnified view of “double halo sign,” consisting of rounded area of normal parenchyma or rounded ground-glass opacity (black arrowhead) surrounded by internal thin rim of consolidation (white arrow) and outer thick rim of ground-glass opacity (black arrow) with final target-like appearance.

The patient was treated by antiretroviral therapy with ritonavir (100 mg/day), darunavir (800 mg/day), hydroxychloroquine (200 mg twice/day), and piperacillin-tazobactam (4.5 g four times/day). Because of the progressive improvement of the patient, and to minimize radiation exposure, a follow-up chest CT was not advised and the patient was discharged after 10 days of hospitalization in a stable condition.

DISCUSSION

The gold standard test for the diagnosis of COVID-19 is RT-PCR, as described previously. However, this test has several limitations, including a low and extremely variable sensitivity depending on many factors, such as the site and quality of sampling, duration of disease, patient's immune status, or degree of viral multiplication and an increased turnaround time (at least 24 hours), which can delay the patient isolation and the proper clinical interventions. In this scenario, CT imaging plays a key role in the diagnosis and management of these patients, and several studies have reported a high sensitivity of chest CT not only in patients with confirmed COVID-19 infection, but also in asymptomatic patients with known exposure or in patients with high clinical suspicion but inconclusive laboratory test results (678141516). Based on the current literature, typical CT manifestations of COVID-19 include diffuse or patchy ground-glass opacities, with or without consolidations or thickening of intralobular septa (“crazy paving” pattern), with prevalent peripheral distribution (involving the outer third of the lung) and with multifocal and bilateral involvement. However, the CT findings can change drastically depending on factors, such as duration of the infection and stage of disease, patient's age, and/or pre-existing lung disease (14151617). All the CT signs detected in this case (the “halo sign,” “reversed halo sign,” or “atoll sign”) are reported with variable, but not negligible frequency in COVID-19 pneumonia (1112141516). However, to the best of our knowledge, the CT presentation pattern with areas of OP consisting of a double halo (one solid, the “reversed halo sign” and another of pure ground-glass halo, the “halo sign”) has never been described in the literature pertaining to COVID-19 or in other lung pathologies. We believe this sign represents the pathological spectrum of COVID-19 pneumonia. In fact, as highlighted in some recent studies based on the pathological findings (181920), it is possible to find not only areas of OP in the lungs of these patients corresponding to consolidations with a “reversed halo sign” in CT images, but also extensive thrombotic damage of the pulmonary microcirculation, which can explain both the “halo sign” of the bilateral consolidations and the second ground-glass halo of the lesions in the RLL. In conclusion, large-scale studies focusing on atypical CT manifestations of COVID-19 pneumonia could offer new perspectives for a better understanding of this infection that has rapidly spread worldwide.
  17 in total

1.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

2.  Can Chest CT Features Distinguish Patients With Negative From Those With Positive Initial RT-PCR Results for Coronavirus Disease (COVID-19)?

Authors:  Dandan Chen; Xinqing Jiang; Yong Hong; Zhihui Wen; Shuquan Wei; Guangming Peng; Xinhua Wei
Journal:  AJR Am J Roentgenol       Date:  2020-05-05       Impact factor: 3.959

3.  Interpreting a covid-19 test result.

Authors:  Jessica Watson; Penny F Whiting; John E Brush
Journal:  BMJ       Date:  2020-05-12

4.  Pulmonary nodules and the CT halo sign.

Authors:  S L Primack; T E Hartman; K S Lee; N L Müller
Journal:  Radiology       Date:  1994-02       Impact factor: 11.105

5.  Essentials for Radiologists on COVID-19: An Update-Radiology Scientific Expert Panel.

Authors:  Jeffrey P Kanne; Brent P Little; Jonathan H Chung; Brett M Elicker; Loren H Ketai
Journal:  Radiology       Date:  2020-02-27       Impact factor: 11.105

6.  Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection.

Authors:  Adam Bernheim; Xueyan Mei; Mingqian Huang; Yang Yang; Zahi A Fayad; Ning Zhang; Kaiyue Diao; Bin Lin; Xiqi Zhu; Kunwei Li; Shaolin Li; Hong Shan; Adam Jacobi; Michael Chung
Journal:  Radiology       Date:  2020-02-20       Impact factor: 11.105

7.  Coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) and common lexicon: a proposal based on the imaging data of 37 studies.

Authors:  Sana Salehi; Aidin Abedi; Sudheer Balakrishnan; Ali Gholamrezanezhad
Journal:  Eur Radiol       Date:  2020-04-28       Impact factor: 5.315

8.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

9.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

10.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome.

Authors:  Zhe Xu; Lei Shi; Yijin Wang; Jiyuan Zhang; Lei Huang; Chao Zhang; Shuhong Liu; Peng Zhao; Hongxia Liu; Li Zhu; Yanhong Tai; Changqing Bai; Tingting Gao; Jinwen Song; Peng Xia; Jinghui Dong; Jingmin Zhao; Fu-Sheng Wang
Journal:  Lancet Respir Med       Date:  2020-02-18       Impact factor: 30.700

View more
  2 in total

1.  Differences and Similarities between the Double Halo Sign, the Chest CT Target Sign and the Reversed Halo Sign in Patients with COVID-19 Pneumonia.

Authors:  Edson Marchiori; Diana Penha; Luiz Felipe Nobre; Bruno Hochhegger; Glaucia Zanetti
Journal:  Korean J Radiol       Date:  2021-02-02       Impact factor: 3.500

2.  Clinical Characteristics and CT Findings in 148 Non-COVID-19 Influenza-Like Illness Cases: A Retrospective Control Study.

Authors:  Weizheng Shuai; Xuxin Chen; Yi Shan; Wenping Li; Wei Ma; Qiaohui Lu; Dawei Li
Journal:  Front Public Health       Date:  2021-02-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.